Nivolumab-Induced Periaortitis Demonstrated by FDG PET/CT.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
pubmed:
24
7
2020
medline:
13
11
2020
entrez:
24
7
2020
Statut:
ppublish
Résumé
A 66-year-old man with a history of non-small cell lung cancer treated with nivolumab underwent contrast-enhanced CT and FDG PET/CT. No recurrence was demonstrated; however, soft-tissue thickening that showed delayed contrast enhancement and FDG uptake was detected around an abdominal aortic aneurysm. After discontinuation of nivolumab, the periaortic lesion disappeared within 2 months, indicating nivolumab-induced periaortitis. Immune checkpoint inhibitors such as nivolumab can cause vasculitis and periaortitis, a potentially fatal condition, as immune-related adverse events. The underlying aortic aneurysm may have contributed to genesis of periaortitis. FDG PET/CT can be useful for detecting periaortitis and excluding other forms of vasculitis.
Identifiants
pubmed: 32701815
doi: 10.1097/RLU.0000000000003215
pii: 00003072-202011000-00024
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Nivolumab
31YO63LBSN
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
910-912Références
Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36:1675–1684.
Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–1589.
Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6:865–871.
Crout TM, Lennep DS, Kishore S, et al. Systemic vasculitis associated with immune check point inhibition: analysis and review. Curr Rheumatol Rep. 2019;21:28.
Watanabe R, Zhang H, Berry G, et al. Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol. 2017;312:H1052–H1059.
Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37:2579–2584.
Roy AK, Tathireddy HR, Roy M. Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. BMJ Case Rep. 2017.
Jagadesham VP, Scott DJ, Carding SR. Abdominal aortic aneurysms: an autoimmune disease?Trends Mol Med. 2008;14:522–529.
Oyama-Manabe N, Yabusaki S, Manabe O, et al. IgG4-related cardiovascular disease from the aorta to the coronary arteries: multidetector CT and PET/CT. Radiographics. 2018;38:1934–1948.